Mouse venous thrombosis upon silencing of anticoagulants depends on tissue factor and platelets, not FXII or neutrophils
- 9 May 2019
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 133 (19) , 2090-2099
Abstract
Tissue factor, coagulation factor XII, platelets, and neutrophils are implicated as important players in the pathophysiology of (experimental) venous thrombosis (VT). Their role became evident in mouse models where surgical handlings were required to provoke VT. Combined inhibition of natural anticoagulants antithrombin (Serpinc1) and protein C (Proc) using small interfering (si) RNA without additional triggers also results in a venous thrombotic phenotype in mice, most notably with vessel occlusion in large veins of the head. VT is fatal but is fully rescued by thrombin inhibition. In the present study, we used this VT mouse model to investigate the involvement of tissue factor, coagulation factor XII, platelets, and neutrophils. Antibody-mediated inhibition of tissue factor reduced the clinical features of VT, the coagulopathy in the head, and fibrin deposition in the liver. In contrast, genetic deficiency in and siRNA-mediated depletion of coagulation factor XII did not alter VT onset, severity, or thrombus morphology. Antibody-mediated depletion of platelets fully abrogated coagulopathy in the head and liver fibrin deposition. Although neutrophils were abundant in thrombotic lesions, depletion of circulating Ly6G-positive neutrophils did not affect onset, severity, thrombus morphology, or liver fibrin deposition. In conclusion, VT following inhibition of antithrombin and protein C is dependent on the presence of tissue factor and platelets, but not on coagulation factor XII and circulating neutrophils. This study demonstrates that distinct procoagulant pathways operate in mouse VT, dependent on the triggering stimulus. Key points Tissue factor and platelets are rate-limiting for mouse venous thrombosis following inhibition of antithrombin and protein C. Coagulation factor XII and circulating neutrophils are not rate-limiting in this animal model for venous thrombosis.Keywords
This publication has 53 references indexed in Scilit:
- Circulating Nucleosomes and Neutrophil Activation as Risk Factors for Deep Vein ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- Neutrophil extracellular traps: Is immunity the second function of chromatin?Journal of Cell Biology, 2012
- Modulation of Mouse Coagulation Gene Transcription following Acute In Vivo Delivery of Synthetic Small Interfering RNAs Targeting HNF4α and C/EBPαPLOS ONE, 2012
- Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivoJournal of Experimental Medicine, 2012
- von Willebrand factor–mediated platelet adhesion is critical for deep vein thrombosis in mouse modelsBlood, 2011
- Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasisJournal of Experimental Medicine, 2009
- Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic miceJournal of Thrombosis and Haemostasis, 2009
- Advances in understanding pathogenic mechanisms of thrombophilic disordersBlood, 2008
- Feedback activation of factor XI by thrombin does not occur in plasmaProceedings of the National Academy of Sciences, 2007
- von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veinsBlood, 2006